Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.74 |
| ▸ | MAG | P20916 | 6/20 | 0.47 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.46 |
| ▸ | SELL | P14151 | 1/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.45 |
| ▸ | CD22 | P20273 | 1/20 | 0.43 |
| ▸ | NEU4 | Q8WWR8 | 1/20 | 0.42 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.42 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.42 |
| ▸ | NEU2 | Q9Y3R4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12108941 | 1.00 | NANP (0.74) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL23366254 | 1.00 | NANP (0.74) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL9253179 | 0.92 | NANP (0.63) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL13125452 | 0.91 | NANP (0.74) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL2742889 | 0.91 | NANP (0.74) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL28161285 | 0.91 | NANP (0.74) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL7066109 | 0.91 | NANP (0.74) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL12108940 | 0.91 | NANP (0.74) | NANPMAGSIGLEC7CD22 | |
| SCHEMBL8489507 | 0.91 | NANP (0.74) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL17029902 | 0.91 | NANP (0.74) | NANPMAGSIGLEC7CD22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486497-B2 | Treatment of immunocompromised conditions | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-11-08 | — | — | US | disclosed |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-07-07 | — | — | US | disclosed |
| US-9254322-B2 | Compositions comprising E-selectin antagonists and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-02-09 | — | — | US | disclosed |
| US-20120202762-A1 | METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8227425-B2 | Antiviral compounds | THERAPICON SRL (IT) | 2012-07-24 | — | — | US | disclosed |
| US-20110257380-A1 | GLYCOMIMETIC REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-8026222-B2 | Use of oligosaccharide compound or glycomimetic compound wherein a cyclohexane derivative is incorporated therein; treating inflammatory, vascular, and skin disorders such as diabetes, atherosclerosis, dermatitis, graft versus host disease, and lymphomas | GLYCOMIMETICS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE | 2011-01-27 | — | — | US | disclosed |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE (AU) | 2011-01-06 | — | — | US | disclosed |
| US-20100029579-A1 | ANTIVIRAL COMPOUNDS | THERAPICON SRL (IT) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELL | NANP 748/4885MAG 1778/4885SIGLEC7 19/4885 |
| US-20100029579-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, ZC3HAV1, NT5E | NANP 198/4885MAG 3426/4885SIGLEC7 77/4885 |
| US-20120202762-A1 | METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | FUT6, ENGASE, FUT5 | NANP 186/4885MAG 173/4885SIGLEC7 73/4885 |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELPLG | NANP 632/4885MAG 1675/4885SIGLEC7 20/4885 |
| US-20110257380-A1 | GLYCOMIMETIC REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | FUT6, B3GNT2, FUT5 | NANP 82/4885MAG 163/4885SIGLEC7 77/4885 |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | SELL, SELP, SELE | NANP 1362/4885MAG 979/4885SIGLEC7 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.